Framatome backs Global Morpho Pharma's high-capacity Lutetium-177 separation process
In a significant stride towards enhancing cancer treatment technologies, Framatome has announced a collaboration with Global Morpho Pharma to develop a high-capacity technology for the purification of non-carrier-added (n.c.a.) Lutetium-177 (Lu-177), a crucial medical radioisotope. This partnership is poised to meet the surging demand for Lu-177 and foster advancements in cancer therapies.